New edition of the Czech Pharmacopoeia 2023 and what preceded it
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Czech Pharmacopoeia 2023 now follows a new waiver concept, impacting its Special Part. Only selected European Pharmacopoeia articles are translated and published, with full publication of the General and National Parts.
Area Of Science
- Pharmacopoeia Standards
- Pharmaceutical Regulation
- Drug Quality Control
Background
- The Czech Pharmacopoeia (ČL) is a key regulatory document for pharmaceuticals in the Czech Republic.
- Previous versions followed a comprehensive translation and publication model for European Pharmacopoeia (Ph. Eur.) content.
- The 2023 edition introduces significant changes in its structure and content dissemination.
Purpose Of The Study
- To outline the changes implemented in the Czech Pharmacopoeia 2023.
- To explain the new waiver concept adopted for the European Part of the ČL.
- To clarify the selective publication approach for specific pharmacopoeial articles.
Main Methods
- The 2023 edition of the Czech Pharmacopoeia was prepared adhering to a new waiver concept.
- The Special Part of the European Part of the ČL is now subject to selective translation and publication.
- The Pharmacopoeia Commission of the Ministry of Health, with expert input, determined the selection criteria for these articles.
Main Results
- The Czech Pharmacopoeia 2023 is mandatory from December 1, 2023.
- The Special Part of the European Pharmacopoeia is published selectively, not in full.
- The General Part of the European Pharmacopoeia and the National Part of the Czech Pharmacopoeia are published in full.
Conclusions
- The implementation of the waiver concept in the Czech Pharmacopoeia 2023 streamlines the publication of European standards.
- Selective publication of the Special Part ensures focus on relevant and critical pharmacopoeial information.
- This updated approach impacts pharmaceutical manufacturers and regulatory bodies relying on the ČL for compliance.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...